MTOR and lung carcinoma: Similarly, AKT and 4EBP1, downstream targets of the PI3K/AKT/mTOR pathway, were inhibited by NT157, further highlighting the antineoplastic potential of this compound in lung cancer, since this signaling pathway is mutated or aberrantly activated in this disease40,41.